New pill shows promise for controlling blood pressure in rare hormone disorder
NCT ID NCT04605549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called CIN-107 in 15 adults with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. Participants took the drug once daily for up to 12 weeks to see if it safely lowered blood pressure. The goal was to find a better way to manage this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CIN-107 (a drug taken as a tablet once daily)
What this could lead to
If it works, this could provide a new treatment option for people with primary aldosteronism to better control their blood pressure.
What could go wrong
This was a small, early-phase study with only 15 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger, longer trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Greenbrae, California, 94904, United States
-
Research Site
San Francisco, California, 94110, United States
-
Research Site
West Hollywood, California, 90048, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Cincinnati, Ohio, 45245, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Dallas, Texas, 75390-9047, United States